Corvus Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $33 from $32 and keeps an Outperform rating on the shares after the company reported full year 2025 results and provided an update across the range of work for its lead clinical-stage ITK inhibitor soquelinitinib. Following very strong results reported in January for SQL in Cohort 4 of Corvus’ AD trial, management is focused on aggressively pushing the candidate forward in AD and other indications. Importantly, following a financing completed in the same month management now has the resources to do so, Oppenheimer adds.